Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 57

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 57
---
 accurately identifying                                                                                                                  
 demand for Kadimastem’s product candidates;                                                                                             |
| ● | obtaining market acceptance                                                                                                             
 of Kadimastem’s product candidates, if approved for marketing, as viable treatment options;                                             |
| ● | negotiating favorable terms                                                                                                             
 in any collaboration, licensing or other arrangements into which Kadimastem may enter;                                                  |
| ● | establishing and nurturing                                                                                                              
 relationships with the leading physicians in the United States; and                                                                     |
| ● | attracting, hiring and                                                                                                                  
 retaining qualified personnel.                                                                                                          |

<div align='center'>38</div>

Kadimastem does not believe that its current cash on hand will be sufficient to fund its projected operating requirements. This raises substantial doubt about its ability to continue as a going concern.

Kadimastem does not believe that its current cash on hand will be sufficient to fund its projected operating requirements. This raises substantial doubt about Kadimastem’s ability to continue as a going concern. If Kadimastem cannot continue as a going concern, its investors may lose their entire investment in its common shares. Until Kadimastem can generate significant revenues, if ever, it expects to satisfy its future cash needs through debt or equity financing. Kadimastem cannot be certain that additional funding will be available to it on acceptable terms, if at all. If funds are not available, Kadimastem may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect to its products.

Even if the Merger is completed, Kadimastem expects that it will need to raise substantial additional funding before it can expect to complete the development of AstroRx® and IsletRx or any other product candidate. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force Kadimastem to delay, limit or terminate its product candidate development efforts or other operations.

Even if the Merger is completed, Kadimastem expects it will require substantial additional capital to commercialize its product candidates. In addition, its operating plans may change as a result of many factors that may not currently be known to it, and it may need to seek additional funds sooner than planned. Kadimastem’s future funding requirements will depend on many factors, including but not limited to:

| ● | its clinical trial results;                                                                                                      |
| ● | the cost, timing and outcomes                                                                                                    
 of seeking marketing approval